Abstract:Importance: Alopecia areata (AA) has been associated with multiple comorbidities, yet information regarding the timing of comorbidity development after AA diagnosis is limited. Objective: To evaluate the prevalence and new-onset incidence of psychiatric and autoimmune comorbidities in patients with AA in the US. Design, setting, and participants: This retrospective cohort analysis used data collected from January 1, 2007, to April 30, 2023, from the Merative MarketScan Research Databases, which contains medical and drug claims data from more than 46 million patients in the US. Data from adolescent and adult patients (aged 12-64 years) diagnosed with AA and patients without AA (ie, controls) were evaluated. For some analyses, patients with AA were matched (1:4) to controls based on sex, age, and geographic region. Main outcomes and measures: Prevalence (at the time of AA diagnosis) and incidence (new onset after AA diagnosis) of psychiatric and autoimmune diseases were reported as percentage of patients. Risk of developing a new-onset psychiatric or autoimmune disease after AA diagnosis was calculated as adjusted hazard ratios (AHRs) with 95% CIs. Results: At baseline, 63 384 patients with AA and 3 309 107 without AA were identified. After matching, there were 16 512 and 66 048 patients in the AA and control groups, respectively, with a mean (SD) age of 36.9 (13.4) years and 50.6% of whom were female. Compared with the unmatched controls, patients with AA had higher prevalence of psychiatric (30.9% vs 26.8%; P < .001) and autoimmune (16.1% vs 8.9%; P < .0001) comorbidities at AA diagnosis; incidence was also higher in patients with AA (without history of these comorbidities) vs the matched control group. Patients with AA vs controls had a significantly higher risk of developing a psychiatric (AHR, 1.3; 95% CI, 1.3-1.4) or autoimmune (AHR, 2.7; 95% CI, 2.5-2.8) comorbidity. Conclusions and relevance: In this cohort study, patients with AA had a higher prevalence of autoimmune and psychiatric comorbidities at AA diagnosis and demonstrated an elevated risk of new-onset autoimmune and psychiatric comorbidities after their diagnosis. These data highlight the most common comorbidities among patients with AA and may help physicians counsel and monitor patients newly diagnosed with AA.

Clinical characteristics and immune profiles of patients with immune-mediated alopecia associated with COVID-19 vaccinations

Alopecia areata following COVID-19 vaccine: a systematic review

The clinical and immunological features of alopecia areata following SARS-CoV-2 infection or COVID-19 vaccines

The Incidence of Alopecia Areata in a COVID-19-Vaccinated Population: A Single-Center Review

A scoping review of alopecia areata and its relationship to COVID-19 vaccinations

The correlation between corona virus disease 2019 and alopecia areata: a literature review

Evaluation of several immune and inflammatory indicators and their association with alopecia areata

Changes and significance of Th1/Th2 and Treg/Th17 cells and their cytokines in patients with alopecia areata

Risks of alopecia areata in long COVID: Binational population‐based cohort studies from South Korea and Japan

Risk of Alopecia Areata After COVID-19

A Case Series and Literature Review of Telogen Effluvium and Alopecia Universalis after the Administration of a Heterologous COVID-19 Vaccine Scheme

Characteristics of immune response profile in patients with immediate allergic and autoimmune urticarial reactions induced by SARS-CoV-2 vaccines

Immune-Mediated and Psychiatric Comorbidities Among Patients Newly Diagnosed With Alopecia Areata

Complete Blood Collection-based Systemic Inflammation Biomarkers as a Severity Biomarker in Alopecia Areata: A Cross-sectional Study

Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management

Causal role of immune cells in alopecia areata: A two‐sample Mendelian randomization study

Alopecia areata exhibits cutaneous and systemic OX40 activation across atopic backgrounds

The Role of Autologous Micrografts Injection from The Scalp Tissue in The Treatment of Covid‐19 Associated Telogen Effluvium: Clinical and Trichoscopic Evaluation

Management of hair loss after severe acute respiratory syndrome coronavirus 2 infection: Insight into the pathophysiology with implication for better management

Alopecia areata and risk of atopic and autoimmune conditions: population-based cohort study

Stratification of alopecia areata reveals involvement of CD4 T cell populations and altered faecal microbiota